My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Sorafenib Tosylate (Bay 43-9006; Nexavar)
    Sorafenib Tosylate (Bay 43-9006; Nexavar)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1003
    CAS #: 475207-59-1 Purity ≥98%

    Description: Sorafenib Tosylate (BAY439006; BAY-439006; BAY549085; BAY-549085; Nexavar; SFN), the tosylate salt of Sorafenib which is an approved anticancer medication, is a potent multi-kinase inhibitor of Raf-1, B-Raf and VEGFR-2 with potential antineoplastic activity. It inhibits Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in enzymatic assays, respectively. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis. Sorafenib was approved in 2005 for use in the treatment of advanced renal cancer. 

    References: Cancer Res, 2004, 64(19), 7099-7109.

    Related CAS#: 284461-73-0 (free base)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)637.03
    FormulaC21H16ClF3N4O3.C7H8O3S
    CAS No.475207-59-1(tosylate);
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 127 mg/mL (199.4 mM)
    Water: <1 mg/mL (slightly soluble or insoluble)
    Ethanol: <1 mg/mL
    SynonymBAY 43-9006 tosylate; BAY549085; BAY-439-006; BAY 549085; BAY-439006 tosylate; BAY 439006; BAY439006 tosylate; BAY-549085; Nexavar; SFN.  


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    GeneralOral administration of Sorafenib tosylate (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity.
    Animal modelFemale NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
    FormulationCremophor EL/ethanol (1:1) as 4-fold (4 × stock solution), and diluted to 1 × with w
    Dosages60 mg/kg
    AdministrationAdministered orally once a day
    Reference[1] Wilhelm SM, et al. Cancer Res, 2004, 64(19), 7099-7109.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Sorafenib Tosylate

    Sorafenib Tosylate

    Sorafenib Tosylate

    The number of nuclei breaking the internal limiting membrane (ILM). A: Controlled group; B: ROP group; C: Vehicle-treated ROP group; D: Low doses sorafenib-treated ROP group; E: Middle doses sorafenib-treated ROP group; F: High dose sorafenib-treated ROP group.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?